Sara E Gombash
Overview
Explore the profile of Sara E Gombash including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gombash S, Lee P, Sawdai E, Lovett-Racke A
Front Neurol
. 2022 Jun;
13:796933.
PMID: 35651353
Vitamin D insufficiency during childhood has been linked to the development of multiple sclerosis (MS), typically an adult-onset inflammatory demyelinating disease of the central nervous system (CNS). Since vitamin D...
2.
Fischer D, Manfredsson F, Kemp C, Cole-Strauss A, Lipton J, Duffy M, et al.
Sci Rep
. 2017 Nov;
7(1):16356.
PMID: 29180681
Subthalamic nucleus deep brain stimulation (STN DBS) protects dopaminergic neurons of the substantia nigra pars compacta (SNpc) against 6-OHDA and MPTP. We evaluated STN DBS in a parkinsonian model that...
3.
Gombash S
Postdoc J
. 2016 Aug;
3(8):1-12.
PMID: 27570787
Gene therapy to the gastrointestinal tract has remarkable potential for treating gastrointestinal disorders that currently lack effective treatments. Adeno-associated viral vectors (AAVs) have been extensively applied to the central nervous...
4.
Fischer D, Gombash S, Kemp C, Manfredsson F, Polinski N, Duffy M, et al.
Methods Mol Biol
. 2015 Nov;
1382:367-82.
PMID: 26611600
Gene therapy methods are increasingly used to model Parkinson's disease (PD) in animals in an effort to test experimental therapeutics within a more relevant context to disease pathophysiology and neuropathology....
5.
Gombash S, Foust K
Methods Mol Biol
. 2015 Nov;
1382:231-7.
PMID: 26611590
Systemic gene delivery is useful for modeling and treatment of a body-wide disease. Recently, it has been shown that certain agents, when delivered systemically, can efficiently target the central nervous...
6.
Iyer C, McGovern V, Murray J, Gombash S, Zaworski P, Foust K, et al.
Hum Mol Genet
. 2015 Aug;
24(21):6160-73.
PMID: 26276812
Spinal Muscular Atrophy (SMA) is an autosomal recessive disorder characterized by loss of lower motor neurons. SMA is caused by deletion or mutation of the Survival Motor Neuron 1 (SMN1)...
7.
Gombash S, Cowley C, Fitzgerald J, Iyer C, Fried D, McGovern V, et al.
Hum Mol Genet
. 2015 Jul;
24(19):5665.
PMID: 26223459
No abstract available.
8.
McGovern V, Iyer C, Arnold W, Gombash S, Zaworski P, Blatnik 3rd A, et al.
Hum Mol Genet
. 2015 Jul;
24(19):5524-41.
PMID: 26206889
Proximal spinal muscular atrophy (SMA) is the most frequent cause of hereditary infant mortality. SMA is an autosomal recessive neuromuscular disorder that results from the loss of the Survival Motor...
9.
Gombash S, Cowley C, Fitzgerald J, Iyer C, Fried D, McGovern V, et al.
Hum Mol Genet
. 2015 Apr;
24(13):3847-60.
PMID: 25859009
The 2007 Consensus Statement for Standard of Care in Spinal Muscular Atrophy (SMA) notes that patients suffer from gastroesophageal reflux, constipation and delayed gastric emptying. We used two mouse models...
10.
Polinski N, Gombash S, Manfredsson F, Lipton J, Kemp C, Cole-Strauss A, et al.
Neurobiol Aging
. 2014 Dec;
36(2):1110-20.
PMID: 25457558
Clinical trials are examining the efficacy of viral vector-mediated gene delivery for treating Parkinson's disease. Although viral vector strategies have been successful in preclinical studies, to date clinical trials have...